Minimal residual disease was “strongly” associated with overall survival at the patient level, researchers reported. Minimal residual disease (MRD) is “a credible intermediate endpoint” for some ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...

Today, OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of ...

Please provide your email address to receive an email when new articles are posted on . A higher correlation was observed between MRD response and OS among non-transplanted patients vs. transplanted ...

Management reiterated plans to initiate two Phase 3 trials under the KOMET-017 protocol for frontline AML in the second half of 2025. The trials will use MRD-negative CR and CR as primary endpoints ...

(ORLANDO, Dec. 6, 2025) Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable ...

Oxford Gene Technology (OGT) has launched its new next-generation sequencing (NGS) SureSeq™ Myeloid MRD Panel for the detection of ultra-low frequency measurable residual disease (MRD)–associated ...

The MarketWatch News Department was not involved in the creation of this content. -- ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 ...